Cargando…

A non-inferiority randomized phase III trial of standard immunotherapy by checkpoint inhibitors vs. reduced dose intensity in responding patients with metastatic cancer: the MOIO protocol study

BACKGROUND: Immunotherapy (IO) has become a standard of care for treating various types of metastatic cancers and has significantly improved clinical outcome. With the exception of metastatic melanoma in complete response for which treatment can be stopped at 6 months, these treatments are currently...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gravis, Gwenaelle, Marino, Patricia, Olive, Daniel, Penault-LLorca, Frederique, Delord, Jean-Pierre, Simon, Clotilde, Lamrani-Ghaouti, Assia, Sabatier, Renaud, Ciccolini, Joseph, Boher, Jean-Marie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Study Protocol
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10155443/ https://www.ncbi.nlm.nih.gov/pubmed/37131154 http://dx.doi.org/10.1186/s12885-023-10881-8

Ejemplares similares

Dysthyroidism during immune checkpoint inhibitors is associated with improved overall survival in adult cancers: data mining of 1385 electronic patient records
por: Beaufils, Mathilde, et al.
Publicado: (2023)

Systemic treatment for metastatic prostate cancer
por: Gravis, Gwenaelle
Publicado: (2019)

Acute skin toxicity of conventional fractionated versus hypofractionated radiotherapy in breast cancer patients receiving regional node irradiation: the real-life prospective multicenter HYPOBREAST cohort
por: Bruand, Marie, et al.
Publicado: (2022)

Breaking down the Contradictory Roles of Histone Deacetylase SIRT1 in Human Breast Cancer
por: Rifaï, Khaldoun, et al.
Publicado: (2018)

Co-targeting EGFR and mTOR with gefitinib and everolimus in triple-negative breast cancer cells
por: El Guerrab, Abderrahim, et al.
Publicado: (2020)

Durable disease control and refractory bullous pemphigoid after immune checkpoint inhibitor discontinuation in metastatic renal cell carcinoma: A case report
por: Mari, Roxane, et al.
Publicado: (2022)

Comparison of different commercial kits for HER2 testing in breast cancer: looking for the accurate cutoff for amplification
por: Cayre, Anne, et al.
Publicado: (2007)

aHIF but not HIF-1α transcript is a poor prognostic marker in human breast cancer
por: Cayre, Anne, et al.
Publicado: (2003)

Testing algorithm for identification of patients with TRK fusion cancer
por: Penault-Llorca, Frédérique, et al.
Publicado: (2019)

Anti-EGFR monoclonal antibodies and EGFR tyrosine kinase inhibitors as combination therapy for triple-negative breast cancer
por: Guerrab, Abderrahim El, et al.
Publicado: (2016)

The Psychological Distress of Cancer Patients following the COVID-19 Pandemic First Lockdown: Results from a Large French Survey
por: Marino, Patricia, et al.
Publicado: (2022)

Protein expression, survival and docetaxel benefit in node-positive breast cancer treated with adjuvant chemotherapy in the FNCLCC - PACS 01 randomized trial
por: Jacquemier, Jocelyne, et al.
Publicado: (2011)

From Targeting Somatic Mutations to Finding Inherited Cancer Predispositions: The Other Side of the Coin
por: Pujol, Pascal, et al.
Publicado: (2019)

Identification of miR-10b, miR-26a, miR-146a and miR-153 as potential triple-negative breast cancer biomarkers
por: Fkih M’hamed, Insaf, et al.
Publicado: (2015)

P-gp expression in brown trout erythrocytes: evidence of a detoxification mechanism in fish erythrocytes
por: Valton, Emeline, et al.
Publicado: (2013)

SIRT1-dependent epigenetic regulation of H3 and H4 histone acetylation in human breast cancer
por: Rifaï, Khaldoun, et al.
Publicado: (2018)

Dual SIRT1 expression patterns strongly suggests its bivalent role in human breast cancer
por: Rifaï, Khaldoun, et al.
Publicado: (2017)

The New Synthetic Serum-Free Medium OptiPASS Promotes High Proliferation and Drug Efficacy Prediction on Spheroids from MDA-MB-231 and SUM1315 Triple-Negative Breast Cancer Cell Lines
por: Dubois, Clémence, et al.
Publicado: (2019)

Quantification of hypoxia-related gene expression as a potential approach for clinical outcome prediction in breast cancer
por: El Guerrab, Abderrahim, et al.
Publicado: (2017)

Cellular Expression of Cyclooxygenase, Aromatase, Adipokines, Inflammation and Cell Proliferation Markers in Breast Cancer Specimen
por: Basu, Samar, et al.
Publicado: (2015)

The Epigenetic Landscape of Promoter Genome-wide Analysis in Breast Cancer
por: Karsli-Ceppioglu, Seher, et al.
Publicado: (2017)

Circulating proteins as predictive and prognostic biomarkers in breast cancer
por: Veyssière, Hugo, et al.
Publicado: (2022)

A new metabolic gene signature in prostate cancer regulated by JMJD3 and EZH2
por: Daures, Marine, et al.
Publicado: (2018)

The Functions of the Demethylase JMJD3 in Cancer
por: Sanchez, Anna, et al.
Publicado: (2021)

Mini-P-gp and P-gp Co-Expression in Brown Trout Erythrocytes: A Prospective Blood Biomarker of Aquatic Pollution
por: Valton, Emeline, et al.
Publicado: (2015)

Differential Impact of EGFR-Targeted Therapies on Hypoxia Responses: Implications for Treatment Sensitivity in Triple-Negative Metastatic Breast Cancer
por: El Guerrab, Abderrahim, et al.
Publicado: (2011)

Adaptation and validation of the memorial anxiety scale for prostate cancer (MAX-PC) in a sample of French men
por: Touzani, Rajae, et al.
Publicado: (2019)

Interest and Limits of [(18)F]ML-10 PET Imaging for Early Detection of Response to Conventional Chemotherapy
por: Jouberton, Elodie, et al.
Publicado: (2021)

The association between adverse events and outcome under checkpoint inhibitors: Where is the deal?
por: Milano, Gerard, et al.
Publicado: (2020)

BRCA1 Induces Major Energetic Metabolism Reprogramming in Breast Cancer Cells
por: Privat, Maud, et al.
Publicado: (2014)

The New Serum-Free OptiPASS(®) Medium in Cold and Oxygen-Free Conditions: An Innovative Conservation Method for the Preservation of MDA-MB-231 Triple Negative Breast Cancer Spheroids
por: Goisnard, Antoine, et al.
Publicado: (2021)

PARP Inhibitors: A Major Therapeutic Option in Endocrine-Receptor Positive Breast Cancers
por: Collet, Laetitia, et al.
Publicado: (2022)

Global analysis of H3K27me3 as an epigenetic marker in prostate cancer progression
por: Ngollo, Marjolaine, et al.
Publicado: (2017)

Highly effective NK cells are associated with good prognosis in patients with metastatic prostate cancer
por: Pasero, Christine, et al.
Publicado: (2015)

Soluble BTN2A1 Is a Potential Prognosis Biomarker in Pre-Treated Advanced Renal Cell Carcinoma
por: Billon, Emilien, et al.
Publicado: (2021)

LightSpot(®)-FL-1 Fluorescent Probe: An Innovative Tool for Cancer Drug Resistance Analysis by Direct Detection and Quantification of the P-glycoprotein (P-gp) on Monolayer Culture and Spheroid Triple Negative Breast Cancer Models
por: Goisnard, Antoine, et al.
Publicado: (2021)

Considerations for treatment duration in responders to immune checkpoint inhibitors
por: Marron, Thomas U, et al.
Publicado: (2021)

Major response with sorafenib in advanced renal cell carcinoma after 14 years of follow-up
por: Guerin, Mathilde, et al.
Publicado: (2013)

Refining the Characterization and Outcome of Pathological Complete Responders after Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer: Lessons from the Randomized Phase III VESPER (GETUG-AFU V05) Trial
por: Culine, Stéphane, et al.
Publicado: (2023)

Chromogenic in situ hybridisation for the assessment of HER2 status in breast cancer: an international validation ring study
por: van de Vijver, Marc, et al.
Publicado: (2007)

Cannot write session to /tmp/vufind_sessions/sess_e50oi4r3nedh24j5dlebl1l53d